Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

References

Page 1

	Year	Citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, New England Journal of Medicine	2013	6.5K
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer William J. Gradishar, Sergei Tjulandin, Neville Davidson, Journal of Clinical Oncology	2005	2.1K
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile Jeffrey S. Hrkach, Daniel D. Von Hoff, Mir Mukkaram Ali, Science Translational Medicine	2012	1.1K
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial David Goldstein, Robert H. El-Maraghi, Pascal Hammel, JNCI Journal of the National Cancer Institute	2015	656
Effect of Vascular Normalization by Antiangiogenic Therapy on Interstitial Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights from a Mathematical Model Rakesh K. Jain, Ricky T. Tong, Lance L. Munn Cancer Research	2007	612
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) Alex Sparreboom, Charity D. Scripture, Vuong Trieu, Clinical Cancer Research	2005	492
Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells <i>in Vitro</i> Dmitri B. Kirpotin, John W. Park, Keelung Hong, Biochemistry Proteinlipid InteractionBreast OncologyPeg SpacerEngineeringImmunotherapeutics	1997	439
Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization Strategy Daryl C. Drummond, Charles O. Noble, Zexiong Guo, Cancer Research	2006	368
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer Helen Lee, Anthony F. Shields, Barry A. Siegel, Clinical Cancer Research	2017	359
Significantly Longer Progression-Free Survival With <i>nab</i>-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer William J. Gradishar, D. Krasnojon, Sergey Cheporov, Journal of Clinical Oncology	2009	338

Page 1